Navigation Links
Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
Date:8/1/2011

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the Canaccord Genuity Annual Growth Conference on August 10, 2011 at 11:30 a.m. Eastern Time at the InterContinental Hotel in Boston.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of this presentation will be accessible in the Investors section of the Company's website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) Tablets, an FDA approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts:
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
858-909-0736

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
6. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
7. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
8. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
9. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
11. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Research and Markets ... "Global DNA Diagnostics Market (Product types, Application, Technology, ... Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, ... report to their offering. This ... techniques, end users and Geography) Global Size, Industry ...
(Date:10/22/2014)... Involution Studios , a healthcare ... new infographic, Understanding Ebola . The goal ... easy to follow informative tool for anyone wanting to ... and prevention. , "As the news has spread in ... outbreak represents not only a healthcare crisis with global ...
(Date:10/22/2014)... October 22, 2014 According to ... by Service Type (Consulting, Integration, Deployment & Support), ... Deployment Model (Public, Private, Others (Hybrid & Community)) ... defines and segments the Cloud Professional Services Market ... forecasting of revenues. It also identifies the drivers ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... The organizers of Pharma,ChemOutsourcing Conference & Exhibition ... and biotech company speakers who,will gather in ... around the,exploding chemical outsourcing activities reshaping R ... industry, reports Apaporis LLC. The,conference program may ...
... 2 ev3 Inc. (Nasdaq:,EVVV), a global endovascular device ... of 2008 and its revised financial,guidance for 2008., ... in the,first quarter of 2008 representing a 65% increase ... 10% increase over the fourth quarter of 2007. The,increase ...
... The timing of the live teleconference should have read: "9:00 am ... follows: Resverlogix Notice ... ... pleased to announce that it will host a live,teleconference on May 8, 2008 at ...
Cached Biology Technology:Chemistry Outsourcing Conference Unveils 90-Speaker Conference Program to Take Place September 8-9 in New Jersey 2ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 2ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 3ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 4ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 5ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 6ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 7ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 8ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 9ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 10ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 11ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 12/C O R R E C T I O N from Source -- Resverlogix Corp./ 2
(Date:10/22/2014)... Calif. , Oct. 20, 2014 The ... United States Air Force Research Laboratory (AFRL), has chosen ... Medicine (AzCIM) at the University of Arizona College of ... research funding.  The AzCIM project,s goal is to assess ... to collect different volumes of sweat under a variety ...
(Date:10/22/2014)... Mass., Oct. 21, 2014 Aware, Inc. (NASDAQ: ... services, today reported financial results for its third quarter ended ... of 2014 was $6.0 million, an increase of 40% compared ... income in the third quarter of 2014 was $4.1 million ... Higher operating income in the current three month period was ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2
... Ill. (March 28, 2011)Deep vein thrombosis, or DVT: it,s ... long plane ride. The Society of Interventional Radiology wants ... serious condition, which can lead to post-thrombotic syndrome, pulmonary ... "Individuals and their doctors need to be ...
... of Utah scientists used invisible infrared light to make ... signals to the brain. The discovery someday might improve ... restore vision, maintain balance and treat movement disorders like ... with optical infrared pulses instead of electrical pulses," which ...
... Researchers have described how the most common gene ... of cancer development and how it can cooperate with ... leukaemia. The researchers suggest that three critical steps ... ones, each subverting a different cellular process. By charting ...
Cached Biology News:Interventional radiologists take lead on reducing disability from dangerous blood clots 2Interventional radiologists take lead on reducing disability from dangerous blood clots 3Interventional radiologists take lead on reducing disability from dangerous blood clots 4Will we hear the light? 2Will we hear the light? 3Will we hear the light? 4Will we hear the light? 5The gene processes that drive acute myeloid leukaemia 2The gene processes that drive acute myeloid leukaemia 3
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
... 9 oligodeoxynucleotides are random ... at the 5' end ... Fluor dyes and they ... microarray spot morphology, hybridization ...
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Mycoplasma tested...
Biology Products: